Weibin Bao

2.1k total citations
27 papers, 1.3k citations indexed

About

Weibin Bao is a scholar working on Rheumatology, Epidemiology and Hepatology. According to data from OpenAlex, Weibin Bao has authored 27 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Rheumatology, 8 papers in Epidemiology and 8 papers in Hepatology. Recurrent topics in Weibin Bao's work include Spondyloarthritis Studies and Treatments (10 papers), Hepatitis C virus research (8 papers) and Liver Disease Diagnosis and Treatment (7 papers). Weibin Bao is often cited by papers focused on Spondyloarthritis Studies and Treatments (10 papers), Hepatitis C virus research (8 papers) and Liver Disease Diagnosis and Treatment (7 papers). Weibin Bao collaborates with scholars based in United States, Switzerland and Germany. Weibin Bao's co-authors include Stephen T. Holgate, Angel FowlerTaylor, William W. Busse, John G. Matthews, Kian Fan Chung, Nizar N. Jarjour, Ratko Djukanović, Susan J. Wilson, John V. Fahy and Monica Kraft and has published in prestigious journals such as Circulation, Hepatology and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

Weibin Bao

26 papers receiving 1.2k citations

Peers

Countries citing papers authored by Weibin Bao

Since Specialization

Citations

This map shows the geographic impact of Weibin Bao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weibin Bao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weibin Bao more than expected).

Fields of papers citing papers by Weibin Bao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Weibin Bao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weibin Bao. The network helps show where Weibin Bao may publish in the future.

Co-authorship network of co-authors of Weibin Bao

This figure shows the co-authorship network connecting the top 25 collaborators of Weibin Bao. A scholar is included among the top collaborators of Weibin Bao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Weibin Bao. Weibin Bao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Safety of Secukinumab from 1 Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical Trials 2024 ·Dermatology and Therapy ·(unknown), (unknown), (unknown), Mark Lebwohl, Alice B. Gottlieb, Philip J. Mease, Atul Deodhar, Weibin Bao, Meryl H. Mendelson, Brian Porter, Deepa H. Chand, Victor Dong	4
2	Impact of hyperuricaemia on patients with psoriatic arthritis treated with secukinumab in the FUTURE 2–5 and MAXIMISE studies 2023 ·RMD Open ·Renaud Felten, (unknown), (unknown), Corine Gaillez, Weibin Bao, Jacques‐Eric Gottenberg, (unknown), Laurent Messer	4
3	Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study 2023 ·RMD Open ·Laura C. Coates, Philip J. Mease, Dafna D. Gladman, Sandra Navarra, Weibin Bao, Corine Gaillez	2
4	E087 Reduced joint synovitis assessment versus the global EULAR OMERACT synovitis score (GLOESS) to predict the response to secukinumab in patients with active psoriatic arthritis and inadequate response to conventional disease-modifying anti-rheumatic drugs: exploratory results from the ULTIMATE trial 2023 ·Lara D. Veeken ·Philip G. Conaghan, Maria Antonietta D’Agostino, Maarten Boers, Esperanza Naredo, Péter Mandl, Philippe Carron, Marina Backhaus, (unknown), Petra Hánová, (unknown), (unknown), Corine Gaillez, Weibin Bao	0
5	Effects of secukinumab on synovitis and enthesitis in patients with psoriatic arthritis: 52-week clinical and ultrasound results from the randomised, double-blind ULTIMATE trial with open label extension 2023 ·Seminars in Arthritis and Rheumatism ·Maria Antonietta D’Agostino, Philippe Carron, Corine Gaillez, Philip G. Conaghan, Esperanza Naredo, (unknown), Ladislav Šenolt, R Burgos-Vargas, Petra Hánová, (unknown), Tomás Cazenave, Maria Stoenoiu, Marina Backhaus, Gaël Mouterde, Weibin Bao, (unknown), Maarten Boers, Georg Schett	10
6	Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data 2022 ·Acta Dermato Venereologica ·Alice B. Gottlieb, Atul Deodhar, Iain B. McInnes, Xenofon Baraliakos, Kristian Reich, Stefan Schreiber, Weibin Bao, Kwaku Marfo, Hanno B. Richards, Luminita Pricop, Abhijit Shete, Vivek Trivedi, Deborah Keefe, C. Papavassilis, (unknown), P. Papanastasiou, Philip J. Mease, Mark Lebwohl	57
7	Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized Study 2022 ·Pediatric Drugs ·Nina Magnolo, Külli Kingo, Vivian Laquer, John Browning, Adam Reich, Jacek C. Szepietowski, Deborah Keefe, P. Papanastasiou, Weibin Bao, (unknown), Manmath Patekar	11
8	26248 Efficacy of secukinumab and adalimumab in psoriatic arthritis patients with moderate-to-severe plaque psoriasis: Results from the EXCEED study 2021 ·Journal of the American Academy of Dermatology ·Alice B. Gottlieb, Joseph F. Merola, Kristian Reich, Frank Behrens, Weibin Bao, Pascale Pellet, Luminita Pricop, Iain B. McInnes	1
9	A Pooled Analysis Reporting the Efficacy and Safety of Secukinumab in Male and Female Patients with Ankylosing Spondylitis 2021 ·Rheumatology and Therapy ·Irene van der Horst‐Bruinsma, Corinne Miceli‐Richard, Jürgen Braun, Helena Marzo‐Ortega, Karel Pavelká, Alan Kivitz, Atul Deodhar, Weibin Bao, Brian Porter, Effie Pournara	10
10	Initiation of Sacubitril/Valsartan Shortly After Hospitalisation for Acutely Decompensated Heart Failure in Patients with Newly Diagnosed ( de novo ) Heart Failure: A Subgroup Analysis of the TRANSITION Study 2019 ·European Journal of Heart Failure ·Michele Senni, Rolf Wachter, Klaus K. Witte, Ewa Straburzyńska‐Migaj, Jan Bělohlávek, Cândida Fonseca, Christian Mueller, Eva Lonn, (unknown), Weibin Bao, Adele Noè, H. Schwende, Dmytro Butylin, Domingo A. Pascual‐Figal	43
11	Abstract 15567: Short-Term Effect on Cardiac Biomarkers of Initiation of Sacubitril/Valsartan in Hospitalized Patients With Heart Failure and Reduced Ejection Fraction: Results of the Transition Study 2018 ·Circulation ·Domingo A. Pascual‐Figal, Michele Senni, Jan Bělohlávek, Dmytro Butylin, Adele Noè, Weibin Bao, Rolf Wachter	2
12	Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis B 2015 ·Advances in Therapy ·Jinlin Hou, (unknown), Guangfeng Shi, Mobin Wan, Zachary Goodman, Deming Tan, Qing Xie, Cheng‐Wei Chen, Lai Wei, Junqi Niu, Qinhuan Wang, Hong Ren, Yuming Wang, Jidong Jia, Weibin Bao, Yuhong Dong, Aldo Trylesinski, Nikolai V. Naoumov	18
13	Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy 2014 ·Journal of Hepatology ·Patrick Marcellin, Karsten Wursthorn, Heiner Wedemeyer, Wan‐Long Chuang, George Lau, (unknown), Cheng‐Yuan Peng, Edward Gane, Seng Gee Lim, Hugo Fainboim, Graham R. Foster, Rifaat Safadi, Mario Rizzetto, Michael P. Manns, Weibin Bao, Aldo Trylesinski, Nikolai V. Naoumov	41
14	Two-year results of a randomized, phase III comparative trial of telbivudine versus lamivudine in Chinese patients 2013 ·Hepatology International ·Jidong Jia, Jinlin Hou, (unknown), Deming Tan, Dao-zhen Xu, Junqi Niu, Xia-qiu Zhou, Yuming Wang, Li Zhu, Cheng‐Wei Chen, Yongwen He, Hong Ren, Mobin Wan, Shanming Wu, Qinhuan Wang, Lai Wei, Weibin Bao, Yuhong Dong, Aldo Trylesinski	13
15	Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B 2011 ·Liver International ·Edward Gane, Yuming Wang, Yun‐Fan Liaw, Jinlin Hou, Satawat Thongsawat, Mobin Wan, (unknown), Jidong Jia, Chao You, Junqi Niu, Nancy Leung, Didier Samuel, Chao‐Wei Hsu, Weibin Bao, Patricia López, Claudio Ávila	37
16	Kinetics of Hepatitis B Surface Antigen Decline During 3 Years of Telbivudine Treatment in Hepatitis B e Antigen–Positive Patients 2010 ·Hepatology ·Karsten Wursthorn, (unknown), Antonio Riva, Zachary Goodman, Patricia López, Weibin Bao, Michael P. Manns, Heiner Wedemeyer, Nikolai V. Naoumov	170
17	Baseline characteristics and early on-treatment response predict the outcomes of 2years of telbivudine treatment of chronic hepatitis B 2009 ·Journal of Hepatology ·Stefan Zeuzem, Edward Gane, Yun‐Fan Liaw, Seng Gee Lim, A DIBISCEGLIE, Marı́a Buti, Anuchit Chutaputti, J. Rasenack, Jinlin Hou, Christopher O’Brien, Tuan Nguyen, Jidong Jia, Thierry Poynard, Bruce Belanger, Weibin Bao, Nikolai V. Naoumov	156
18	Safety and tolerability of indacaterol in asthma: A randomized, placebo-controlled 28-day study 2007 ·Respiratory Medicine ·А. Г. Чучалин, (unknown), Kai Richter, Norbert Krug, Ronald Dahl, (unknown), R. Cameron, Weibin Bao, Mark Higgins, Ralph Woessner, Andre van As	36
19	Safety, tolerability and efficacy of indacaterol, a novel once-daily β2-agonist, in patients with COPD: A 28-day randomised, placebo controlled clinical trial 2006 ·Pulmonary Pharmacology & Therapeutics ·Jutta Beier, Pascal Chanez, Jean‐Benoît Martinot, A. J. M. Schreurs, Ružena Tkáčová, Weibin Bao, Damon Jack, Mark Higgins	67
20	Effects of Treatment with Anti-immunoglobulin E Antibody Omalizumab on Airway Inflammation in Allergic Asthma 2004 ·American Journal of Respiratory and Critical Care Medicine ·Ratko Djukanović, Susan J. Wilson, Monica Kraft, Nizar N. Jarjour, (unknown), Kian Fan Chung, Weibin Bao, Angel FowlerTaylor, John G. Matthews, William W. Busse, Stephen T. Holgate, John V. Fahy	498

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact